Cytogenetic characteristics of and prognosis for acute myeloid leukemia in 107 children

[1] Zhai XW, Cheng FWT, Lee V, Leung WK, Ng MHL, Tsang KS, et al. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. Pediatr Hematol Oncol. 2011; 28:269–78. ZhaiXW ChengFWT LeeV LeungWK NgMHL TsangKS Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children Pediatr Hematol Oncol 2011 28 269 78 10.3109/08880018.2010.53324921345081 Search in Google Scholar

[2] Vedi A, Mitchell R, Shanmuganathan S, Oswald C, Marshall GM, Trahair T, et al. Increased survival for children with acute myeloid leukemia results from improved postrelapse treatment. J Pediatr Hematol Oncol. 2018; 40:541–7. VediA MitchellR ShanmuganathanS OswaldC MarshallGM TrahairT Increased survival for children with acute myeloid leukemia results from improved postrelapse treatment J Pediatr Hematol Oncol 2018 40 541 7 10.1097/MPH.000000000000121529794644 Search in Google Scholar

[3] Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012; 120:3187–205. CreutzigU van den Heuvel-EibrinkMM GibsonB DworzakMN AdachiS de BontE Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel Blood 2012 120 3187 205 10.1182/blood-2012-03-36260822879540 Search in Google Scholar

[4] Kairiene I, Pasauliene R, Lipunova N, Vaitkeviciene G, Rageliene L, Rascon J. Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience. Eur J Pediatr. 2017; 176:1329–37. KairieneI PasaulieneR LipunovaN VaitkevicieneG RagelieneL RasconJ Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience Eur J Pediatr 2017 176 1329 37 10.1007/s00431-017-2978-928812191 Search in Google Scholar

[5] Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012; 119:5980–8. RubnitzJE How I treat pediatric acute myeloid leukemia Blood 2012 119 5980 8 10.1182/blood-2012-02-392506338301322566607 Search in Google Scholar

[6] Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2018; 18:277–93. KleinK de HaasV KaspersGJL Clinical challenges in de novo pediatric acute myeloid leukemia Expert Rev Anticancer Ther 2018 18 277 93 10.1080/14737140.2018.142809129338495 Search in Google Scholar

[7] Lins MM, Mello MJG, Ribeiro RC, De Camargo B, de Fátima Pessoa Militão, de Albuquerque M, Thuler LCS. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country. Ann Hematol. 2019; 98:1403–11. LinsMM MelloMJG RibeiroRC De CamargoB de Fátima PessoaMilitão de AlbuquerqueM ThulerLCS Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country Ann Hematol 2019 98 1403 11 10.1007/s00277-019-03661-730915498 Search in Google Scholar

[8] Xing S, Wang B, Gao Y, Li M, Wang T, Sun Y, et al. Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. Int J Lab Hematol. 2019; 41:485–92. XingS WangB GaoY LiM WangT SunY Cytogenetics and associated mutation profile in patients with acute monocytic leukemia Int J Lab Hematol 2019 41 485 92 10.1111/ijlh.1303031099482 Search in Google Scholar

[9] Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, et al. Multiplex fusion gene testing in pediatric acute myeloid leukemia. Pediatr Int. 2018; 60:47–51. Iijima-YamashitaY MatsuoH YamadaM DeguchiT KiyokawaN ShimadaA Multiplex fusion gene testing in pediatric acute myeloid leukemia Pediatr Int 2018 60 47 51 10.1111/ped.1345129105243 Search in Google Scholar

[10] Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017; 129:3051–8. VujkovicM AttiyehEF RiesRE GoodmanEK DingY KavcicM Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report Blood 2017 129 3051 8 10.1182/blood-2017-03-772384546584028411282 Search in Google Scholar

[11] McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019; 33:1934–43. McNeerNA PhilipJ GeigerH RiesRE LavalléeVP WalshM Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Leukemia 2019 33 1934 43 10.1038/s41375-019-0402-3668754530760869 Search in Google Scholar

[12] Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013; 122:170–8. PessionA MasettiR RizzariC PuttiMC CasaleF FagioliF Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia Blood 2013 122 170 8 10.1182/blood-2013-03-49162123673857 Search in Google Scholar

[13] Subspecialty Group of Hematology Diseases; Society of Pediatrics; Chinese Medical Association; Editorial Board of Chinese Journal of Pediatrics, Lungjun G, et al. [Recommendations for diagnosis and treatment of acute myelocytic leukemia in children]. Zhonghua Er Ke Za Zhi. [Chin J Pediatr]. 2006; 44:877–8. [in Chinese] Subspecialty Group of Hematology Diseases; Society of Pediatrics; Chinese Medical Association; Editorial Board of Chinese Journal of Pediatrics LungjunG [Recommendations for diagnosis and treatment of acute myelocytic leukemia in children] Zhonghua Er Ke Za Zhi. [Chin J Pediatr] 2006 44 877 8 [in Chinese] Search in Google Scholar

[14] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Br J Cancer. 2015; 112:251–9. CollinsGS ReitsmaJB AltmanDG MoonsKG Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement Br J Cancer 2015 112 251 9 10.1161/CIRCULATIONAHA.114.014508429722025561516 Search in Google Scholar

[15] O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15:926–57. O’DonnellMR TallmanMS AbboudCN AltmanJK AppelbaumFR ArberDA Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2017 15 926 57 10.6004/jnccn.2017.011628687581 Search in Google Scholar

[16] Jastaniah W, Bayoumy M, Alsultan A, Al Daama S, Ballourah W, Al-Anzi F, et al. Identifying prognostic factors that influence outcome of childhood acute myeloid leukemia in first relapse in Saudi Arabia: results of the multicenter SAPHOS Study. Clin Lymphoma Myeloma Leuk. 2018; 18:773–80. JastaniahW BayoumyM AlsultanA Al DaamaS BallourahW Al-AnziF Identifying prognostic factors that influence outcome of childhood acute myeloid leukemia in first relapse in Saudi Arabia: results of the multicenter SAPHOS Study Clin Lymphoma Myeloma Leuk 2018 18 773 80 10.1016/j.clml.2018.09.00130340992 Search in Google Scholar

[17] Ruan M, Wang Y-Q, Zhang L, Zou Y, Zhu X-F. [Analyses of karyotypic characteristics and prognosis in pediatric acute myeloblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. [Chin J Hematol]. 2012; 33:725–8. [in Chinese, English abstract]. RuanM WangY-Q ZhangL ZouY ZhuX-F [Analyses of karyotypic characteristics and prognosis in pediatric acute myeloblastic leukemia] Zhonghua Xue Ye Xue Za Zhi. [Chin J Hematol] 2012 33 725 8 [in Chinese, English abstract]. Search in Google Scholar

[18] Sandahl JD, Kjeldsen E, Abrahamsson J, Ha SY, Heldrup J, Jahnukainen K, et al. Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study. Genes Chromosomes Cancer. 2014; 53:667–75. SandahlJD KjeldsenE AbrahamssonJ HaSY HeldrupJ JahnukainenK Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study Genes Chromosomes Cancer 2014 53 667 75 10.1002/gcc.2217724753324 Search in Google Scholar

[19] So C-C, Wan TS, Chow JL, Hui K-C, Choi WW, Lam CC, Chan L-C. A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia—evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients. Cancer Genet. 2011; 204:430–8. SoC-C WanTS ChowJL HuiK-C ChoiWW LamCC ChanL-C A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia—evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients Cancer Genet 2011 204 430 8 10.1016/j.cancergen.2011.06.00321962893 Search in Google Scholar

[20] Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014; 28:1449–58. KrauthMT EderC AlpermannT BacherU NadarajahN KernW High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome Leukemia 2014 28 1449 58 10.1038/leu.2014.424402164 Search in Google Scholar

[21] Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DKH, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010; 28:2674–81. HarrisonCJ HillsRK MoormanAV GrimwadeDJ HannI WebbDKH Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12 J Clin Oncol 2010 28 2674 81 10.1200/JCO.2009.24.899720439644 Search in Google Scholar

[22] Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005; 106:447–453. TestiAM BiondiA Lo CocoF MoletiML GionaF VignettiM GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children Blood 2005 106 447 453 10.1182/blood-2004-05-197115677559 Search in Google Scholar

[23] Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol. 2007; 78:468–76. BettsDR AmmannRA HirtA HengartnerH Beck-PopovicM KuhneT The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG) Eur J Haematol 2007 78 468 76 10.1111/j.1600-0609.2007.00854.x17419750 Search in Google Scholar

[24] Kömür M, Erbey F, Bayram I, Tanyeli A. Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. Asian Pac J Cancer Prev. 2010; 11:1393–5. KömürM ErbeyF BayramI TanyeliA Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia Asian Pac J Cancer Prev 2010 11 1393 5 Search in Google Scholar

[25] Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology Am Soc Hematol Educ Program. 2017; 2017:37–44. MoariiM PapaemmanuilE Classification and risk assessment in AML: integrating cytogenetics and molecular profiling Hematology Am Soc Hematol Educ Program 2017 2017 37 44 10.1182/asheducation-2017.1.37614260529222235 Search in Google Scholar

[26] Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, et al. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi [Chin J Hematol]. 2018; 39:9–14. [in Chinese, English abstract] GongXY WangY LiuBC WeiH LiCW LiQH [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements] Zhonghua Xue Ye Xue Za Zhi [Chin J Hematol] 2018 39 9 14 [in Chinese, English abstract] Search in Google Scholar

[27] He J, Xue Y, He H, Li J, Song X, Huang Y, et al. [Clinical and biological characteristics in childhood acute myeloid leukemia with 8;21 translocation]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi [Chin J Med Genetics]. 2004; 21:512–4. [in Chinese, English abstract]. HeJ XueY HeH LiJ SongX HuangY [Clinical and biological characteristics in childhood acute myeloid leukemia with 8;21 translocation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi [Chin J Med Genetics] 2004 21 512 4 [in Chinese, English abstract]. Search in Google Scholar

[28] Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018; 59:2273–86. PatnaikMM The importance of FLT3 mutational analysis in acute myeloid leukemia Leuk Lymphoma 2018 59 2273 86 10.1080/10428194.2017.139931229164965 Search in Google Scholar

[29] Wang CL, Ding BJ, Jiang L, Yin CX, Zhong QX, Yu GP, et al. Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat. Neoplasma. 2015; 62:864–71. WangCL DingBJ JiangL YinCX ZhongQX YuGP Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat Neoplasma 2015 62 864 71 10.4149/neo_2015_10526458322 Search in Google Scholar

[30] Kim M, Kim J, Kim JR, Han E, Park J, Lim J, et al. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1. Mol Biol Rep. 2015; 42:451–6. KimM KimJ KimJR HanE ParkJ LimJ FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1 Mol Biol Rep 2015 42 451 6 10.1007/s11033-014-3786-125287662 Search in Google Scholar

[31] Ding C, Chen S-N, Macleod RAF, Drexler HG, Nagel S, Wu D-P, et al. MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. Ups J Med Sci. 2018; 123:19–27. DingC ChenS-N MacleodRAF DrexlerHG NagelS WuD-P MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death Ups J Med Sci 2018 123 19 27 10.1080/03009734.2018.1440037590146529493383 Search in Google Scholar

[32] Debaize L, Jakobczyk H, Avner S, Gaudichon J, Rio A-G, Sérandour AA, et al. Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. Nucleic Acids Res. 2018; 46:11214–228. DebaizeL JakobczykH AvnerS GaudichonJ RioA-G SérandourAA Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation Nucleic Acids Res 2018 46 11214 228 10.1093/nar/gky756626545830500954 Search in Google Scholar

[33] Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, et al. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Ann Hematol. 2019; 98:83–91. KawashimaN AkashiA NagataY KiharaR IshikawaY AsouN Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study Ann Hematol 2019 98 83 91 10.1007/s00277-018-3492-530251205 Search in Google Scholar